Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Elanco Animal Health Inc (NYSE: ELAN) was $17.43 for the day, up 1.93% from the previous closing price of $17.1. In other words, the price has increased by $1.93 from its previous closing price. On the day, 5.88 million shares were traded. ELAN stock price reached its highest trading level at $17.475 during the session, while it also had its lowest trading level at $17.085.
Ratios:
Our analysis of ELAN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.07 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.99. For the most recent quarter (mrq), Quick Ratio is recorded 1.40 and its Current Ratio is at 2.60. In the meantime, Its Debt-to-Equity ratio is 0.62 whereas as Long-Term Debt/Eq ratio is at 0.61.
On December 09, 2024, UBS started tracking the stock assigning a Buy rating and target price of $18.UBS initiated its Buy rating on December 09, 2024, with a $18 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 11 ’25 when Todd S and Jennifer G Young Li bought 49,333 shares for $16.82 per share.
Kurzius Lawrence Erik bought 10,000 shares of ELAN for $109,000 on Mar 07 ’25. The Director now owns 101,459 shares after completing the transaction at $10.90 per share. On Mar 11 ’25, another insider, Kurzius Lawrence Erik, who serves as the Director of the company, bought 10,000 shares for $10.20 each. As a result, the insider paid 102,000 and bolstered with 111,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELAN now has a Market Capitalization of 8659468288 and an Enterprise Value of 12329462784. As of this moment, Elanco’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.97, and their Forward P/E ratio for the next fiscal year is 17.66. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.69. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.93 while its Price-to-Book (P/B) ratio in mrq is 1.28. Its current Enterprise Value per Revenue stands at 2.75 whereas that against EBITDA is 14.643.
Stock Price History:
The Beta on a monthly basis for ELAN is 1.61, which has changed by 0.23792613 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, ELAN has reached a high of $17.29, while it has fallen to a 52-week low of $8.02. The 50-Day Moving Average of the stock is 20.68%, while the 200-Day Moving Average is calculated to be 41.49%.
Shares Statistics:
ELAN traded an average of 5.67M shares per day over the past three months and 7710500 shares per day over the past ten days. A total of 496.65M shares are outstanding, with a floating share count of 492.11M. Insiders hold about 0.95% of the company’s shares, while institutions hold 100.05% stake in the company. Shares short for ELAN as of 1753920000 were 23961864 with a Short Ratio of 4.22, compared to 1751241600 on 25007355. Therefore, it implies a Short% of Shares Outstanding of 23961864 and a Short% of Float of 6.670000399999999.
Earnings Estimates
Its stock is currently analyzed by 10.0 different market analysts. The consensus estimate for the next quarter is $0.13, with high estimates of $0.15 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.91 and $0.82 for the fiscal current year, implying an average EPS of $0.88. EPS for the following year is $0.99, with 13.0 analysts recommending between $1.05 and $0.95.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $1.1B to a low estimate of $1.08B. As of the current estimate, Elanco Animal Health Inc’s year-ago sales were $1.03BFor the next quarter, 8 analysts are estimating revenue of $1.08B. There is a high estimate of $1.09B for the next quarter, whereas the lowest estimate is $1.06B.
A total of 11 analysts have provided revenue estimates for ELAN’s current fiscal year. The highest revenue estimate was $4.62B, while the lowest revenue estimate was $4.47B, resulting in an average revenue estimate of $4.59B. In the same quarter a year ago, actual revenue was $4.44BBased on 11 analysts’ estimates, the company’s revenue will be $4.81B in the next fiscal year. The high estimate is $4.89B and the low estimate is $4.65B.
